# OnCo record nct05652686 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05652686/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05652686", "NCT05652686" ;
  schema:name "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)"@en ;
  schema:alternateName "SKYBRIDGE"@en ;
  schema:description "A phase 1/2 trial of Peluntamig, Carboplatin, Etoposide in small-cell lung cancer and prostate cancer, run by Phanes Therapeutics, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05652686/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05652686> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-09-05" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/extrapulmonary-nec/> ;
  onco:drugs <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/lurbinectedin/> ;
  onco:companies <https://onco.cc/companies/phanes-therapeutics/> .